Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Extract summary only
RNS Number : 9944W
Angle PLC
29 April 2021
For Immediate Release 29 April 2021
ANGLE plc
("ANGLE" or "the Company")
Preliminary Results for the year ended 31 December 2020
FDA SUBSTANTIVE REVIEW PROGRESSING
LAUNCH OF CLINICAL LABORATORY SERVICES
FIRST LARGE-SCALE CONTRACT WITH PHARMA CUSTOMER USING THE PARSORTIX SYSTEM IN CLINICAL TRIALS
PATIENT ENROLMENT COMPLETED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31 December 2020.
Angle PLC First large-scale pharma services contract secured
Source: UK Regulatory (RNS & others)
TIDMAGL
RNS Number : 6588V
Angle PLC
16 April 2021
For immediate release 16 April 2021
ANGLE plc ("the Company")
FIRST LARGE-SCALE PHARMA SERVICES CONTRACT SECURED
Contract worth up to US$1.2 million with potential for further contracts from the same customer
Parsortix system being utilised in cancer drug trials for liquid biopsy longitudinal monitoring which is not possible with tissue biopsies
Thu, 15th Apr 2021 16:10
RNS Number : 6429V
Angle PLC
15 April 2021
For immediate release
15 April 2021
ANGLE plc ("the Company")
Notice of Preliminary Results and Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2020 on Thursday 29 April 2021.
A virtual meeting and webcast for analysts will be held at 10:00 am BST on Thursday 29 April 2021. If you wish to attend, please register in advance and log on to the webcast approximately 5 minutes before 10.00 am on the day of the results. Details of how to attend can be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations. This link is to watch and listen only as Q&A time is reserved for analysts. A recording of the webcast will be made available on ANGLE's website following the results meeting.
For further information ANGLE:
Angle PLC ANGLE's Parsortix system showcased at AACR 2021
Source: RNS Non-Regulatory
TIDMAGL
Angle PLC
12 April 2021
For immediate release 12 April 2021
ANGLE plc ("the Company")
ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE
Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021
Seeing Machines Limited Issue of shares and total voting rights
Source: UK Regulatory (RNS & others)
TIDMSEE
RNS Number : 9927S
Seeing Machines Limited
22 March 2021
22 March 2021
Seeing Machines Limited
Issue of shares and total voting rights
Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, annouces that it has issued 68,403,430 new ordinary shares of no par value each (the "New Ordinary Shares") to US based Toronado Fund, LP, at a price of 10.5 pence per New Ordinary Share, raising gross proceeds of approximately US$10 million (the "Purchase"). The Purchase, conducted at a premium, was introduced and arranged by Beech Hill Securities.
The net proceeds of the Purchase further strengthens the Company's balance sheet and is expected to fund the business through to profitability.
Application will been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur and dealings will commence in the New Ordinary Shares at 8.00 a.m. on 26 March 2021.
Total Voting Rights
Following Admission, the Company's issued and fully paid share capital will consist of 3,805,617,804 ordinary shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company will be 3,805,617,804. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Paul McGlone, CEO of Seeing Machines, commented: "We warmly welcome Toronado as a shareholder, and are delighted that a second high quality US investor has chosen to invest in our Company, underpinning our strategy to broaden the representation of institutions on our register. The capital raised will enable Seeing Machines to develop and collaborate on additional growth opportunities which are incremental to our core plans.
"Following initial interest from the US late last year, we continue to see increasing enthusiasm around driver monitoring technology and, in particular, Seeing Machines' growing market opportunity."
Enquiries:
Seeing Machines Limited Notice of Results and Investor Presentation
Source: UK Regulatory (RNS & others)
TIDMSEE
RNS Number : 8421S
Seeing Machines Limited
19 March 2021
Seeing Machines Limited
19 March 2021
Notice of Results and Investor Presentation
SEEING MACHINES LIMITED is pleased to announce that CEO Paul McGlone, and CFO Naomi Rule, will provide a live presentation relating to H1 FY2021 Results Presentation via the Investor Meet Company platform on 31st Mar 2021 at 8:00am BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet SEEING MACHINES LIMITED via:
https://www.investormeetcompany.com/seeing-machines-limited/register-investor
Investors who already follow SEEING MACHINES LIMITED on the Investor Meet Company platform will automatically be invited.
https://twitter.com/missy_cummings/status/1370173423150829569?s=20